INmune Bio, Inc. announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease.
The results will be presented at the 18th Clinical Trials on Alzheimer's Disease conference (CTAD), reinforcing the evidence base of XPro1595 in high-inflammation Alzheimer's patients.
The data support the Company's strategy of targeting inflammation-driven Alzheimer's disease, a significant unmet need.
XPro1595's Mechanism
Selective neutralizing soluble TNF (sTNF) interrupts neurodegenerative cascade in AD driven by inflammation.
PerpPD+ Findings
Show trend towards slowed neurodegeneration progression in patients receiving XPro1595, indicating potential therapeutic benefits.
Cortical Disarray Measurement
Dose-compliant participants showed trend for reduced cortical disarray, aligning with XPro1595's mechanism of reducing innate immune dysfunction.
- The PerpPD+ imaging analysis demonstrated a potential slowing of neurodegeneration progression in early Alzheimer's patients with high inflammatory burden.
- Results indicate XPro1595's efficacy in attenuating cortical disarray, a key hallmark associated with neurodegeneration.
- Promising implications for XPro1595 as a disease-modifying therapy for Alzheimer's patients with elevated neuroinflammation.
INmune Bio's neuroimaging data presented at the CTAD conference reinforces the therapeutic potential of XPro1595 in addressing inflammation-driven Alzheimer's disease, highlighting a promising outlook for future Alzheimer's treatments.